Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Aims/hypothesis The aim of the study was to examine the impact of statin or omega-3-acid ethyl esters 90 (omega-3 EE90; omega-3-acid ethyl esters 90 refers to a mixture of ethyl esters of n-3 fatty acids) on estimated cardiovascular disease (CVD) risk in community-based people with type 2 diabetes but without known CVD and not taking lipid-lowering therapy. Methods A central computer randomised 800 patients in 59 UK general practices to atorvastatin (n∈=∈401, 20 mg/day) or placebo (n∈=∈399) and omega-3 EE90 (n∈=∈397, 2 g/day) or placebo (n∈=∈403) in a concealed factorial manner. Participants with LDL-cholesterol < 2.6 mmol/l, triacylglycerol < 1.5 mmol/l and estimated 10-year CVD risk < 20% were compared at 4 months. Results Mean (SD) age was 63.5 (11.7) years, HbA 1c 6.9 (1.1) % and known diabetes duration (median [interquartile range]) was 4 (2-8) years. Fifty-seven per cent were men, 90% white and 74% had an estimated 10-year CVD risk ≥20%. Of 732 patients with 4-month data, more allocated atorvastatin (n∈=∈371) compared with placebo (n∈=∈361) achieved LDL-cholesterol < 2.6 mmol/l (91% vs 24%, p∈ < ∈0.001) and had estimated 10-year CVD risks < 20% (38% vs 26%, p∈ < ∈0.001). No differences were seen between those allocated omega-3 EE90 (n∈=∈371) compared with placebo (n∈=∈361) for participants achieving triacylglycerol < 1.5 mmol/l (65% vs 60%, p∈=∈0.18) or estimated 10-year CVD risks < 20% (34% vs 30%, p∈=∈0.18). There were no side effects of note. Conclusions/ interpretation Many community-based diabetic patients without known CVD remain at high CVD risk despite statin treatment and require additional risk-reduction strategies. The impact of omega-3 EE90 on CVD risk will remain uncertain until clinical endpoint trial results are available. Trial registration: ISRCT no. 76737502 Funding: The study was funded by Pfizer. © 2008 Springer-Verlag.

Original publication

DOI

10.1007/s00125-008-1179-5

Type

Journal article

Journal

Diabetologia

Publication Date

01/01/2009

Volume

52

Pages

50 - 59